GlassScriptPhysician profile
David L Wertheim
NPI 1285738849
$33,592.32
in general payments reported to CMS, 2019-2025
48 companies · $17K in 2025
The $17K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $1,397 · 2021: $2,504 · 2022: $3,447 · 2023: $4,052 · 2024: $4,017 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $13K · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,571.41 |
| Food and Beverage | $12,515.52 |
| Education | $128.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $15,369.62 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $3,554.21 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $1,995.13 | 2019-2025 | |
| Pfizer INC. | $1,448.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,167.87 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Optinose US, INC. | $1,014.45 | 2019-2024 | |
| Amgen INC. | $920.05 | 2021-2025 | Tezspire, Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $776.97 | 2020-2025 | Cuvitru, Glassia, Takhzyro |
| Genentech USA, INC. | $689.67 | 2019-2025 | Xolair |
| Kaleo, INC. | $675.13 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $673.42 | 2019-2025 | Xembify |
| Incyte Corporation | $652.82 | 2021-2025 | Opzelura |
| Biocryst US Sales Co., LLC | $484.77 | 2022-2025 | Orladeyo |
| Alk-Abello, INC | $320.80 | 2020-2025 | Odactra, Grastek, Ragwitek |
| Octapharma USA, INC. | $317.52 | 2020-2025 | Panzyga, Cutaquig |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wertheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.